AXGN vs IART
AXGN: Axogen is a medical technology company dedicated to advancing the field of peripheral nerve repair through its portfolio of nerve allografts, conduits, and wrap technologies. IART: A global medical technology leader specializing in neurosurgery and regenerative tissue reconstruction.
Side-by-side fundamentals
| Metric | AXGN | IART | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $36.18 | $13.41 | |
| Market cap | $1.9B | $1.0B | |
| Net margin FY2025, SEC XBRL | -7.0% | -31.6% | AXGN higher |
| Gross margin FY2025, SEC XBRL | +74.3% | n/a | |
| Operating margin FY2025, SEC XBRL | -3.5% | -30.2% | AXGN higher |
| ROE FY2025, SEC XBRL | -12.2% | -49.5% | AXGN higher |
| ROA FY2025, SEC XBRL | -7.1% | -14.3% | AXGN higher |
| Debt / equity as of 2026-09-03 | 0.00 | 1.79 | AXGN lower |
| Revenue growth (YoY) as of 2026-09-03 | +23.6% | +1.6% | AXGN higher |
| Revenue CAGR (3y) SEC XBRL | +17.6% | +1.6% | AXGN higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 0.68 | 1.38 | |
| 1-year return as of 2026-10-08 close | +110.8% | -9.5% | AXGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.